Ramachandran Thirucote

TR is a co-founder and the Chairman and Chief Technology Officer of LIPAC Oncology. TR has more than 30 years of experience in the design, development and launch of innovative biopharmaceutical products ranging from tablets and capsules to injectable and oral formulations, as well as ointments, creams and nasal drug delivery systems. Prior to founding LIPAC Oncology he held executive leadership positions at a variety of companies, focusing on the strategic development and commercialization of pharmaceutical products. Most recently he developed and managed an innovative virtual company model at ROXRO Pharma where he brought the drug-device combination SprixTM from early development to FDA approval. Prior to that, TR designed and launched a strategic program for the development of pharmaceutical products for private start-up companies at SRI International. He also successfully led the oncology pipeline at Agouron Pharmaceuticals, which was acquired by Pfizer for more than $2 billion. At Thermedics, TR spearheaded the development of a high profile, trauma reducing anti-infective wound dressing for the Department of Defense.

TR started his career with ASTRA-IDL in India, where he implemented quality design systems for manufacturing. TR attended the Massachusetts College of Pharmacy and Health Sciences where he earned a doctoral degree in Industrial Pharmacy, as well as Masters and Bachelors degree in Pharmaceutical Sciences. TR is a published scientist, an active consultant to the U.S. National Institutes of Health, and a member of the Special Emphasis Review Panel for the National Institute of Allergy and Infectious Diseases.